IL126589A - 2,3-disubstituted-4-(3h)-quinazolinones, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating or preventing cerebral deficits - Google Patents
2,3-disubstituted-4-(3h)-quinazolinones, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating or preventing cerebral deficitsInfo
- Publication number
- IL126589A IL126589A IL12658997A IL12658997A IL126589A IL 126589 A IL126589 A IL 126589A IL 12658997 A IL12658997 A IL 12658997A IL 12658997 A IL12658997 A IL 12658997A IL 126589 A IL126589 A IL 126589A
- Authority
- IL
- Israel
- Prior art keywords
- quinazolinones
- disubstituted
- medicaments
- treating
- preparation
- Prior art date
Links
- -1 2,3-disubstituted-4-(3h)-quinazolinones Chemical class 0.000 title 1
- 230000002490 cerebral effect Effects 0.000 title 1
- 230000006735 deficit Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Paints Or Removers (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1773896P | 1996-05-15 | 1996-05-15 | |
| PCT/IB1997/000134 WO1997043276A1 (en) | 1996-05-15 | 1997-02-17 | Novel 2,3 disubstituted-4(3h)-quinazolinones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL126589A0 IL126589A0 (en) | 1999-08-17 |
| IL126589A true IL126589A (en) | 2003-06-24 |
Family
ID=21784266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12658997A IL126589A (en) | 1996-05-15 | 1997-12-17 | 2,3-disubstituted-4-(3h)-quinazolinones, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating or preventing cerebral deficits |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6303615B1 (de) |
| EP (1) | EP0901487B9 (de) |
| JP (1) | JP3241388B2 (de) |
| KR (1) | KR100375155B1 (de) |
| CN (2) | CN1103772C (de) |
| AP (1) | AP1148A (de) |
| AR (1) | AR007118A1 (de) |
| AT (1) | ATE242232T1 (de) |
| AU (1) | AU730503B2 (de) |
| BG (1) | BG102999A (de) |
| BR (1) | BR9709085A (de) |
| CA (1) | CA2252907C (de) |
| CZ (1) | CZ295565B6 (de) |
| DE (1) | DE69722613T2 (de) |
| DK (1) | DK0901487T3 (de) |
| DZ (1) | DZ2237A1 (de) |
| EA (1) | EA002905B1 (de) |
| ES (1) | ES2198546T3 (de) |
| GT (1) | GT199700049A (de) |
| HN (1) | HN1997000052A (de) |
| HR (1) | HRP970261B1 (de) |
| HU (1) | HUP9902148A3 (de) |
| ID (1) | ID17149A (de) |
| IL (1) | IL126589A (de) |
| IS (1) | IS4881A (de) |
| MA (1) | MA26430A1 (de) |
| NO (1) | NO985293L (de) |
| OA (1) | OA10918A (de) |
| PL (1) | PL330042A1 (de) |
| PT (1) | PT901487E (de) |
| SI (1) | SI0901487T1 (de) |
| SK (1) | SK284108B6 (de) |
| TN (1) | TNSN97087A1 (de) |
| TR (1) | TR199802296T2 (de) |
| TW (1) | TW539675B (de) |
| WO (1) | WO1997043276A1 (de) |
| YU (1) | YU19197A (de) |
| ZA (1) | ZA974156B (de) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3299990B2 (ja) * | 1997-02-28 | 2002-07-08 | ファイザー・プロダクツ・インク | 神経変性状態およびｃｎｓ外傷関連状態の処置のための３−ヘテロアリール−４（３ｈ）−キナゾリノン類のアトロプ異性体 |
| ID22711A (id) * | 1997-02-28 | 1999-12-09 | Pfizer Prod Inc | Atropisomer dari 3-aril-4(3h)-kinazolinon dan penggunaannya sebagai antagonis reseptor-ampa |
| US6060479A (en) * | 1997-06-09 | 2000-05-09 | Pfizer Inc | Quinazoline-4-one AMPA antagonists |
| EP0900567A3 (de) * | 1997-09-05 | 2001-05-02 | Pfizer Products Inc. | Quinazolin-4-on AMPA Antagonisten zur Behandlung von motorischen Fehlfunktionen verbunden mit Dopaminagonist Therapie |
| IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
| JPH11279158A (ja) * | 1998-02-09 | 1999-10-12 | Pfizer Prod Inc | キナゾリン―４―オン誘導体の製造方法 |
| CA2362385C (en) | 1999-02-15 | 2009-08-11 | Eisai Co., Ltd. | Heterodiazinon compound |
| US6890930B1 (en) * | 1999-09-28 | 2005-05-10 | 3-Dimensional Pharmaceuticals, Inc. | Quinazolinones |
| US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US20020061897A1 (en) | 2000-03-30 | 2002-05-23 | Elliott Richard L. | Neuropeptide Y antagonists |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| PT1300396E (pt) | 2000-06-12 | 2009-04-20 | Eisai R&D Man Co Ltd | Compostos de 1,2-di-hidropiridina, processos para a sua preparação e sua utilização |
| US7053216B2 (en) * | 2001-11-19 | 2006-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of Rho C activity |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| AU2003213092A1 (en) | 2002-02-15 | 2003-09-09 | Smithkline Beecham Corporation | Syntheses of quinazolinones |
| EP1503993A4 (de) | 2002-05-09 | 2006-05-03 | Cytokinetics Inc | Verbindungen, verfahren und zusammensetzungen |
| JP2005530785A (ja) | 2002-05-09 | 2005-10-13 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、及び方法 |
| EP1513820A4 (de) | 2002-05-23 | 2006-09-13 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren |
| EP1556357A4 (de) | 2002-06-14 | 2006-09-13 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren |
| US7211580B2 (en) * | 2002-07-23 | 2007-05-01 | Cytokinetics, Incorporated | Compounds, compositions, and methods |
| JP2006501306A (ja) | 2002-09-30 | 2006-01-12 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| JP2007513154A (ja) | 2003-12-08 | 2007-05-24 | サイトキネティクス・インコーポレーテッド | 化合物、組成物及び方法 |
| EP1761540B1 (de) | 2004-05-13 | 2016-09-28 | Icos Corporation | Chinazolinone als inhibitoren der humanen phosphatidylinosit-3-kinase delta |
| MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
| EP1954283A2 (de) * | 2005-11-04 | 2008-08-13 | Hydra Biosciences, Inc. | Verbindungen zum modulieren der trpv3-funktion |
| CA2663436A1 (en) | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| ES2523925T3 (es) * | 2007-09-26 | 2014-12-02 | Celgene Corporation | Derivados de quinazolinona sustituidos en posición 6, 7 u 8 y composiciones que los contienen y métodos de uso de los mismos |
| CN101925585B (zh) | 2008-01-30 | 2013-04-17 | 新丰制药株式会社 | 喹唑啉-2,4-二酮衍生物及含有所述衍生物的用于预防和治疗脑神经疾病的药物组合物 |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| KR20160091440A (ko) | 2008-11-13 | 2016-08-02 | 길리아드 칼리스토가 엘엘씨 | 혈액 종양에 대한 요법 |
| CA2756347A1 (en) | 2009-03-24 | 2010-09-30 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
| SG175259A1 (en) | 2009-04-20 | 2011-11-28 | Gilead Calistoga Llc | Methods of treatment for solid tumors |
| AU2010276160A1 (en) | 2009-07-21 | 2012-02-09 | Gilead Calistoga Llc | Treatment of liver disorders with PI3K inhibitors |
| WO2013105985A1 (en) * | 2011-02-28 | 2013-07-18 | Philadelphia Health & Education Corporation | Small molecule inhibitors of rad51 recombinase and methods thereof |
| EA025407B1 (ru) | 2012-03-05 | 2016-12-30 | Джилид Калистога Ллс | Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она |
| NZ720867A (en) | 2013-12-20 | 2018-01-26 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
| WO2015095605A1 (en) | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
| JP6455995B2 (ja) | 2014-06-13 | 2019-01-23 | ギリアード サイエンシーズ， インコーポレイテッド | ホスファチジルイノシトール３−キナーゼ阻害剤 |
| CN113226286B (zh) | 2018-12-14 | 2024-08-20 | 卫材R&D管理有限公司 | 1,2-二氢吡啶化合物的水基药物制剂 |
| WO2021154966A1 (en) | 2020-01-29 | 2021-08-05 | Kamari Pharma Ltd. | Compounds and compositions for use in treating skin disorders |
| CN113831335A (zh) * | 2020-06-24 | 2021-12-24 | 北京大学 | 吡啶[2,3-d]并嘧啶-4-(3H)-酮类化合物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1195321B (de) * | 1962-03-16 | 1965-06-24 | Troponwerke Dinklage & Co | Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten |
| DE1670416A1 (de) * | 1966-12-30 | 1971-02-11 | Chem Fab Von Heyden Gmbh Muenc | Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten |
| GB1298603A (en) | 1970-04-06 | 1972-12-06 | Karamchand Premchand Private | Quinazolinone derivatives |
| AU543928B2 (en) * | 1981-01-16 | 1985-05-09 | Masayuki Ishikawa | 4(311)-quinazolinone derivatives |
| GB9022785D0 (en) | 1990-10-19 | 1990-12-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO1992013535A1 (en) * | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Anticonvulsant substituted quinazolones |
| US5284957A (en) | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| KR100304177B1 (ko) | 1993-05-06 | 2001-11-22 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | (1,2,4)트리아졸로(4,3-a)퀴녹살린화합물,이의제조방법및이를함유하는약제학적조성물_ |
| GB9400680D0 (en) * | 1994-01-14 | 1994-03-09 | Sandoz Ltd | Improvements in or relating to organic compounds |
| ID22711A (id) | 1997-02-28 | 1999-12-09 | Pfizer Prod Inc | Atropisomer dari 3-aril-4(3h)-kinazolinon dan penggunaannya sebagai antagonis reseptor-ampa |
-
1997
- 1997-02-17 PT PT97901749T patent/PT901487E/pt unknown
- 1997-02-17 AU AU15549/97A patent/AU730503B2/en not_active Ceased
- 1997-02-17 AT AT97901749T patent/ATE242232T1/de not_active IP Right Cessation
- 1997-02-17 BR BR9709085A patent/BR9709085A/pt not_active Application Discontinuation
- 1997-02-17 WO PCT/IB1997/000134 patent/WO1997043276A1/en not_active Ceased
- 1997-02-17 DE DE69722613T patent/DE69722613T2/de not_active Expired - Fee Related
- 1997-02-17 SK SK1520-98A patent/SK284108B6/sk unknown
- 1997-02-17 CA CA002252907A patent/CA2252907C/en not_active Expired - Fee Related
- 1997-02-17 HU HU9902148A patent/HUP9902148A3/hu unknown
- 1997-02-17 EP EP97901749A patent/EP0901487B9/de not_active Expired - Lifetime
- 1997-02-17 CZ CZ19983526A patent/CZ295565B6/cs not_active IP Right Cessation
- 1997-02-17 DK DK97901749T patent/DK0901487T3/da active
- 1997-02-17 US US09/180,732 patent/US6303615B1/en not_active Expired - Fee Related
- 1997-02-17 PL PL97330042A patent/PL330042A1/xx unknown
- 1997-02-17 JP JP54068297A patent/JP3241388B2/ja not_active Expired - Fee Related
- 1997-02-17 EA EA199800923A patent/EA002905B1/ru not_active IP Right Cessation
- 1997-02-17 ES ES97901749T patent/ES2198546T3/es not_active Expired - Lifetime
- 1997-02-17 SI SI9730555T patent/SI0901487T1/xx unknown
- 1997-02-17 KR KR10-1998-0709205A patent/KR100375155B1/ko not_active Expired - Fee Related
- 1997-02-17 CN CN97194654A patent/CN1103772C/zh not_active Expired - Fee Related
- 1997-02-17 TR TR1998/02296T patent/TR199802296T2/xx unknown
- 1997-04-08 TW TW086104460A patent/TW539675B/zh active
- 1997-04-21 HN HN1997000052A patent/HN1997000052A/es unknown
- 1997-04-29 GT GT199700049A patent/GT199700049A/es unknown
- 1997-05-13 AR ARP970102001A patent/AR007118A1/es not_active Application Discontinuation
- 1997-05-14 ZA ZA974156A patent/ZA974156B/xx unknown
- 1997-05-14 MA MA24613A patent/MA26430A1/fr unknown
- 1997-05-14 ID IDP971603A patent/ID17149A/id unknown
- 1997-05-14 YU YU19197A patent/YU19197A/sh unknown
- 1997-05-14 DZ DZ970085A patent/DZ2237A1/fr active
- 1997-05-14 TN TNTNSN97087A patent/TNSN97087A1/fr unknown
- 1997-05-15 AP APAP/P/1997/001003A patent/AP1148A/en active
- 1997-05-15 HR HR970261A patent/HRP970261B1/xx not_active IP Right Cessation
- 1997-12-17 IL IL12658997A patent/IL126589A/xx not_active IP Right Cessation
-
1998
- 1998-10-27 IS IS4881A patent/IS4881A/is unknown
- 1998-11-06 OA OA9800216A patent/OA10918A/en unknown
- 1998-11-13 NO NO985293A patent/NO985293L/no unknown
- 1998-12-08 BG BG102999A patent/BG102999A/xx unknown
-
2002
- 2002-09-05 CN CN02131946A patent/CN1420114A/zh active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0104676A3 (en) | Compositions for the treatment of anorectal disorders and their use | |
| HUP0100069A3 (en) | 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders | |
| IL114586A (en) | Droloxifene for use in the treatment of cardiovascular diseases and pharmaceutical compositions comprising same | |
| HUP0100737A3 (en) | Use of phytosterol for preventing and delaying the onset of alzheimer's disease and phytosterol containing pharmaceutical compositions | |
| NO20001001D0 (no) | Poly (ADP-ribose) polymerase ("PARP") inhibitorer, fremgangsmõte og farmasøytiske sammensetninger for behandling av neurale og kardiovaskulære vevskader | |
| IL122733A0 (en) | Pharmaceutical compositions for use in the treatment of allergic asthma | |
| IL113844A (en) | N-(alpha-ETHYLBENZYL)-3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE AND ITS USE IN THE PREPARATION OF MEDICAMENTS | |
| IL130424A (en) | Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis | |
| HUP0100786A3 (en) | Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | |
| HU9600162D0 (en) | Use of an antagonist of cgrp in cosmetic, pharmaceutical or dermatological composition and the cosmetic compositions | |
| IL127943A0 (en) | Pharmaceutical and cosmetic composition for the treatment of skin disorders | |
| HRP20030046A2 (en) | Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome | |
| GB0015235D0 (en) | Compositions for the treatment of skin and anorectal conditions | |
| PL344246A1 (en) | Novel pharmaceutical composition for use in emergency treatment and preparation method thereof | |
| IL133784A (en) | Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer | |
| HUP0003851A3 (en) | Pharmaceutical composition for the treatment or prevention of glomerulopathy | |
| IL107978A0 (en) | Mannitol derivatives processes for the preparation thereof and pharmaceutical compositions containing the same | |
| AU7528001A (en) | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders | |
| HUP9901434A3 (en) | Substituted benzylamines and their use for the preparation of medicaments for treating depression | |
| HUP9900584A3 (en) | Novel benzoyl guanidine derivatives, process for their preparation and their use in the preparation of medicines | |
| ZA97741B (en) | Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders. | |
| KR100213963B1 (en) | Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis | |
| HUP0000935A3 (en) | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones and their use for the treatment of neurodegenerative and cns-trauma related conditions | |
| EP0676200A3 (de) | Verwendung von Eliprodil und von seinem Enantiomeren zur Herstellung einer Mittels zur Behandlung von peripheren Neuropathien und von zentralen neurodegenerativen Erkrankungen. | |
| HUP0004331A3 (en) | Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| MM9K | Patent not in force due to non-payment of renewal fees |